• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

6-Iodoquinoline-3-carboxylic acid: A Key Compound in Modern Pharmaceutical Research

6-Iodoquinoline-3-carboxylic acid (CAS No. 1416440-04-4) has emerged as a pivotal molecule in the development of novel therapeutic agents, particularly in the fields of oncology and neurodegenerative disease treatment. This compound belongs to the class of quinoline derivatives, which are known for their diverse biological activities, including antimicrobial, antitumor, and anti-inflammatory properties. The iodo substituent at the 6-position and the carboxylic acid functional group at the 3-position contribute significantly to its unique pharmacological profile.

Recent studies have highlighted the potential of 6-Iodoquinoline-3-carboxylic acid in modulating specific signaling pathways associated with cancer progression. For instance, a 2023 publication in *Journal of Medicinal Chemistry* demonstrated that this compound exhibits selective inhibition of the PI3K/AKT/mTOR pathway, a critical driver of tumor cell survival and proliferation. This finding underscores its relevance as a candidate for targeted cancer therapies.

The quinoline scaffold is a well-established structural motif in pharmaceutical chemistry, with compounds like quinolone antibiotics and quinazoline derivatives being widely used in clinical practice. However, the introduction of the iodo group in 6-Iodoquinoline-3-carboxylic acid enhances its metabolic stability and bioavailability, making it a promising lead compound for further optimization.

Advances in computational drug discovery have enabled researchers to explore the molecular interactions of 6-Iodoquinoline-3-carboxylic acid with various protein targets. A 2024 study published in *Bioorganic & Medicinal Chemistry* utilized molecular docking simulations to identify its binding affinity for the EGFR (Epidermal Growth Factor Receptor), a key oncogenic target in lung and breast cancers. These findings suggest its potential as an inhibitor of EGFR tyrosine kinase activity.

The carboxylic acid group in 6-Iodoquinoline-3-carboxylic acid plays a dual role in its pharmacological activity. It not only facilitates ionization and solubility but also contributes to the compound's ability to interact with metal ion chelating agents. This property has been exploited in the design of multitarget drugs that address complex disease mechanisms, such as Alzheimer's disease, where metal ion dysregulation is a key pathological feature.

Recent breakthroughs in structure-based drug design have further enhanced the understanding of 6-Iodoquinoline-3-carboxylic acid's mechanism of action. A 2023 study in *ACS Medicinal Chemistry Letters* revealed that the compound selectively binds to the ATP-binding cassette (ABC) transporters, which are implicated in multidrug resistance in cancer cells. This discovery opens new avenues for the development of chemosensitizing agents that can overcome treatment resistance.

The iodo substitution in 6-Iodoquinoline-3-carboxylic acid also influences its electrophilic aromatic substitution reactivity, making it a versatile building block for drug conjugation strategies. Researchers have explored its use in prodrug design, where the compound is modified to enhance its solubility and reduce toxicity while maintaining therapeutic efficacy.

Current research efforts are focused on optimizing the pharmacokinetic properties of 6-Iodoquinoline-3-carboxylic acid through structure-activity relationship (SAR) studies. A 2024 review in *Drug Discovery Today* highlighted the importance of hydrophobicity and hydrophilicity balance in determining the compound's blood-brain barrier (BBB) permeability, which is crucial for its application in neurodegenerative diseases.

Additionally, the quinoline core of 6-Iodoquinoline-3-carboxylic acid has been investigated for its antioxidant properties. A 2023 study in *Free Radical Biology and Medicine* showed that the compound exhibits free radical scavenging activity, which could contribute to its therapeutic potential in oxidative stress-related conditions such as diabetes and cardiovascular diseases.

The carboxylic acid functionality also allows for conjugation with various targeting ligands, enabling the development of site-specific drug delivery systems. This approach has been explored in the context of nanomedicine, where 6-Iodoquinoline-3-carboxylic acid is functionalized to enhance its targeting efficiency in tumor tissues.

Recent advances in high-throughput screening (HTS) have facilitated the rapid identification of compounds like 6-Iodoquinoline-3-carboxylic acid with desired biological activities. A 2024 study in *Nature Communications* demonstrated the use of machine learning algorithms to predict the in vitro and in vivo efficacy of the compound, significantly accelerating the drug discovery process.

The iodo group in 6-Iodoquinoline-3-carboxylic acid also influences its photophysical properties, which have been explored in photodynamic therapy (PDT) applications. Researchers are investigating the compound's potential as a photosensitizer that can generate reactive oxygen species (ROS) upon light irradiation, offering a novel approach for cancer treatment.

Finally, the synthetic accessibility of 6-Iodoquinoline-3-carboxylic acid has been optimized through asymmetric catalysis and green chemistry methodologies. These advancements are critical for the large-scale production of the compound, ensuring its viability as a therapeutic agent in clinical settings.

As research into 6-Iodoquinoline-3-carboxylic acid continues to evolve, its potential applications in oncology, neurology, and metabolic disorders are becoming increasingly evident. The compound's unique chemical properties and the ongoing innovations in drug discovery technologies position it as a promising candidate for future therapeutic developments.

Further studies are needed to fully elucidate the mechanistic pathways of 6-Iodoquinoline-3-carboxylic acid and to evaluate its clinical safety profile. Collaborative efforts between academic institutions, pharmaceutical companies, and regulatory agencies will be essential to translate these findings into effective treatments for patients.

In conclusion, 6-Iodoquinoline-3-carboxylic acid represents a significant advancement in the field of pharmaceutical chemistry. Its multifaceted properties and the innovative approaches being applied to its development underscore its potential as a versatile therapeutic agent. As research progresses, it is anticipated that this compound will play a pivotal role in addressing some of the most challenging medical conditions of our time.

For more information on the latest research and developments related to 6-Iodoquinoline-3-carboxylic acid, please refer to the following scientific literature and resources:

• ACS Medicinal Chemistry Letters
• Nature Communications
• Bioorganic & Medicinal Chemistry
• Free Radical Biology and Medicine

These resources provide detailed insights into the chemical and biological properties of 6-Iodoquinoline-3-carboxylic acid, as well as its potential applications in drug development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)